WEKO3
アイテム
Validation of MRI biomarker of white matter degeneration for ALS clinical trials
https://repo.qst.go.jp/records/80770
https://repo.qst.go.jp/records/807705fb4cec9-d864-4cdd-b1f0-f71c64a59a0d
Item type | 会議発表論文 / Conference Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-10-21 | |||||
タイトル | ||||||
タイトル | Validation of MRI biomarker of white matter degeneration for ALS clinical trials | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_5794 | |||||
資源タイプ | conference paper | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Shinoto, Hitoshi
× Shinoto, Hitoshi× Armon, Carmel× Shinoto, Hitoshi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased. Amyotrophic lateral sclerosis (ALS) is a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord.1 It is part of the ALS–frontotemporal dementia spectrum of disorders that dismantle systematically the behavioral-executive-motor neuronal supernetwork. Measures of strength or function have served as primary outcome measures for most ALS treatment trials.2 Advanced neuroimaging techniques offer the potential to aid in diagnosing ALS and monitoring disease progression. Diffusion tensor imaging (DTI), a robust MRI tool for in vivo analysis of white matter (WM) neuronal tracts, has been applied successfully to study ALS in cross-sectional and longitudinal single-center cohort studies.3–6 Regional reduction of DTI metrics such as fractional anisotropy (FA) has been used as a marker for axonal degeneration and myelin degradation. |
|||||
書誌情報 |
Neurology 巻 95, 号 8, p. 327-328, 発行日 2020-08 |
|||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1212/WNL.0000000000010252 |